Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
Although routine clinical markers are used routinely to determine the stage of human immunodeficiency virus (HIV) disease, their use in monitoring response to antiretroviral therapy is poorly defined. Selected clinical markers were evaluated for their ability to predict first-line antiretroviral therapy success. No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4+ cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy.
Bagchi
Shashwatee
S
Division of Geographic Medicine and Center for AIDS Research, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kempf
Mirjam C
MC
Westfall
Andrew O
AO
Maherya
Anastasiya
A
Willig
James
J
Saag
Michael S
MS
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis*; D018791:CD4 Lymphocyte Count; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D015415:Biomarkers; D006454:Hemoglobins; D012367:RNA, Viral